Compare GWH & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWH | SKYE |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 29.1M |
| IPO Year | N/A | 2013 |
| Metric | GWH | SKYE |
|---|---|---|
| Price | $1.02 | $0.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.25 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 680.4K | 142.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.99 | N/A |
| Revenue Next Year | $1,328.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $0.57 |
| 52 Week High | $13.87 | $5.75 |
| Indicator | GWH | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 46.64 |
| Support Level | $0.74 | $0.71 |
| Resistance Level | $1.22 | $0.83 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 74.61 | 32.00 |
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. It develops and manufactures long-duration energy storage systems based on iron flow battery technology. The company's batteries use earth-abundant materials, including iron, salt, and water, and are designed for high cycle life and recyclability. It operates as a single business operating segment, which includes all activities related to the design, engineering, and manufacturing of the company's long duration energy storage products. The company's revenue is derived from the sale of its energy storage products and from service contracts.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.